Literature DB >> 15759205

Pancreatic head cancer: accuracy of CT in determination of resectability.

G Karmazanovsky1, V Fedorov, V Kubyshkin, A Kotchatkov.   

Abstract

BACKGROUND: Pancreatic cancer is a devastating disease whose early detection remains difficult. There is no 100% reliable imaging test to diagnose and stage pancreatic cancer. We assessed the surgical value of contrast-enhanced spiral computed tomography (CT) in predicting the resectability and survival rates of patients who had pancreatic head cancer.
METHODS: Eighty-nine patients who had pancreatic head cancer were investigated with spiral CT. Based on the preoperative CT results, we assigned patients to one of three CT groups based on resectability.
RESULTS: A correlation between classification of CT resectability and intraoperative finding was found in 83% of patients. The sensitivity, specificity, negative predictive value, positive predictive value, and accuracy of spiral CT in identifying predictive unresectability were 79%, 82%, 91%, 62%, and 81%, respectively. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of CT in diagnosis of vascular invasion were 94%, 84.2%, 94%, 84%, and 91.3%, respectively.
CONCLUSION: The use of CT in the evaluation of pancreatic tumors provides valuable preoperative assessment of surgical resectability and should be performed for clinical examination. Classifying patients by tumor resectability on CT helps to estimate more precisely the tumor stage and to prognosticate survival rates of these patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15759205     DOI: 10.1007/s00261-004-0279-z

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  40 in total

1.  An MRI-driven practice: a new perspective on MRI for the evaluation of adenocarcinoma of the head of the pancreas.

Authors:  Elliot B Tapper; Diego Martin; N Volkan Adsay; David Kooby; Bobby Kalb; Juan M Sarmiento
Journal:  J Gastrointest Surg       Date:  2010-05-14       Impact factor: 3.452

2.  Preoperative assessment of para-aortic lymph node metastasis in patients with pancreatic cancer.

Authors:  Hisashi Imai; Ryuichiro Doi; Hiroyuki Kanazawa; Naoko Kamo; Masayuki Koizumi; Toshihiko Masui; Yasuhiro Iwanaga; Yoshiya Kawaguchi; Yasutsugu Takada; Hiroyoshi Isoda; Shinji Uemoto
Journal:  Int J Clin Oncol       Date:  2010-03-16       Impact factor: 3.402

3.  Diagnostic value of IMP3 in pancreatic cancer: a meta-analysis.

Authors:  Qianqian Wang; Tao Wang; Zhu Wang; Hong Zheng
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 4.  Detecting early pancreatic cancer: problems and prospects.

Authors:  Suresh T Chari
Journal:  Semin Oncol       Date:  2007-08       Impact factor: 4.929

5.  Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma.

Authors:  Shun Zhang; Yi-Ming Wang; Chuan-Dong Sun; Yun Lu; Li-Qun Wu
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

6.  Diagnostic value of mesothelinin pancreatic cancer: a meta-analysis.

Authors:  Lin Zhu; Yiling Liu; Guangyuan Chen
Journal:  Int J Clin Exp Med       Date:  2014-11-15

7.  Imaging of pancreatic cancer: An overview.

Authors:  Pavan Tummala; Omer Junaidi; Banke Agarwal
Journal:  J Gastrointest Oncol       Date:  2011-09

8.  MDCT findings predicting post-operative residual tumor and survival in patients with pancreatic cancer.

Authors:  Jae Seok Bae; Jung Hoon Kim; Ijin Joo; Won Chang; Joon Koo Han
Journal:  Eur Radiol       Date:  2019-03-21       Impact factor: 5.315

Review 9.  Surgical treatment for advanced pancreatic cancer.

Authors:  Hyung Jun Kwon; Sang Geol Kim
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2012-08-31

10.  Time trends in the treatment and prognosis of resectable pancreatic cancer in a large tertiary referral centre.

Authors:  Giuliano Barugola; Stefano Partelli; Stefano Crippa; Giovanni Butturini; Roberto Salvia; Nora Sartori; Claudio Bassi; Massimo Falconi; Paolo Pederzoli
Journal:  HPB (Oxford)       Date:  2013-03-12       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.